Although the emerging mRNA delivery technique is thought to be feasible to treating any CF patients, independent of underlying mutations, using the mRNA encoding CFTR (Haque et al., 2018; Robinson et al., 2018), this treatment necessitates life-time administration, similarly as do the CFTR modulator therapies, engineered tRNA or ASOs. The gene discussed is CFTR; the disease is cystic fibrosis.